Citius Pharmaceuticals Stock Price on November 25, 2024
| CTXR Stock | USD 3.32 0.28 7.78% |
Below is the normalized historical share price chart for Citius Pharmaceuticals extending back to October 02, 2014. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Citius Pharmaceuticals stands at 3.32, as last reported on the 29th of November, with the highest price reaching 4.11 and the lowest price hitting 3.32 during the day.
If you're considering investing in Citius Stock, it is important to understand the factors that can impact its price. Citius Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.21, which signifies that the company had a -0.21% return per unit of risk over the last 3 months. Citius Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Citius Pharmaceuticals' Risk Adjusted Performance of (0.15), mean deviation of 5.29, and Standard Deviation of 8.45 to double-check the risk estimate we provide.
At this time, Citius Pharmaceuticals' Stock Based Compensation is relatively stable compared to the past year. As of 11/29/2024, Issuance Of Capital Stock is likely to grow to about 26.8 M, while Capital Stock is likely to drop slightly above 101.2 K. . At this time, Citius Pharmaceuticals' Price Book Value Ratio is relatively stable compared to the past year. As of 11/29/2024, Price To Book Ratio is likely to grow to 26.01, though Price Earnings To Growth Ratio is likely to grow to (15.07). Citius Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 6th of July 2017 | 200 Day MA 0.6564 | 50 Day MA 0.4458 | Beta 1.663 |
Citius |
Sharpe Ratio = -0.2067
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CTXR |
Estimated Market Risk
| 8.61 actual daily | 76 76% of assets are less volatile |
Expected Return
| -1.78 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.21 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Citius Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Citius Pharmaceuticals by adding Citius Pharmaceuticals to a well-diversified portfolio.
Price Book 0.3247 | Book Value 0.474 | Enterprise Value 10.2 M | Enterprise Value Ebitda (2.74) | Shares Float 158.2 M |
Related Headline
Hookipa Pharma Headline on 25th of November 2024
Acquisition by Oneill Julie of 9600 shares of Hookipa Pharma... by O'neill Julie
Filed transaction by Hookipa Pharma Director. Grant, award or other acquisition pursuant to Rule 16b-3
Citius Pharmaceuticals Valuation on November 25, 2024
It is possible to determine the worth of Citius Pharmaceuticals on a given historical date. On November 25, 2024 Citius was worth 4.6 at the beginning of the trading date compared to the closed value of 3.34. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Citius Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Citius Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Citius Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Citius Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 3.35 | 3.75 | 2.74 | 3.35 | 645,576 | |
11/25/2024 | 4.60 | 4.61 | 3.28 | 3.34 | 5,907,752 |
| 3.58 | 4.25 | 2.55 | 4.15 | 1,728,526 |
| Backtest Citius Pharmaceuticals | | | Citius Pharmaceuticals History | | | Citius Pharmaceuticals Valuation | Previous | Next |
Citius Pharmaceuticals Trading Date Momentum on November 25, 2024
| On November 26 2024 Citius Pharmaceuticals was traded for 4.15 at the closing time. The top price for the day was 4.25 and the lowest listed price was 2.55 . The trading volume for the day was 1.7 M. The trading history from November 26, 2024 was a factor to the next trading day price gain. The overall trading delta against the next closing price was 24.25% . The overall trading delta against the current closing price is 7.78% . |
Citius Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Citius Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Citius Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Citius financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Citius Pharmaceuticals Stock history
Citius Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Citius is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Citius Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Citius Pharmaceuticals stock prices may prove useful in developing a viable investing in Citius Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 174 M | 182.7 M | |
| Net Loss | -30.3 M | -28.8 M |
Citius Pharmaceuticals Quarterly Net Working Capital |
|
Citius Pharmaceuticals Stock Technical Analysis
Citius Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Citius Pharmaceuticals Period Price Range
Low | November 29, 2024
| High |
0.00 | 0.00 |
Citius Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Citius Pharmaceuticals November 29, 2024 Market Strength
Market strength indicators help investors to evaluate how Citius Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Citius Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Citius Pharmaceuticals stock market strength indicators, traders can identify Citius Pharmaceuticals entry and exit signals to maximize returns
Citius Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Citius Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Citius Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Citius to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.15) | |||
| Jensen Alpha | (1.93) | |||
| Total Risk Alpha | (3.01) | |||
| Treynor Ratio | (1.02) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Citius Stock Analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.